US09071M2052 - ADR
These 10X penny stocks have the potential to mint millionaires with enough capital but buy wisely as the risk is real.
BLRX stock results show that BioLine Rx beat analyst estimates for earnings per share the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioLine Rx (NASDAQ:BLRX) just reported results for the first quarter of 2024.Bi...
- Steady growth in APHEXDA® adoption in first full quarter post-approval - - Among top 80 transplant centers, secured APHEXDA formulary placement to date at...
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing...
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing...
BLRX stock results show that BioLine Rx beat analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioLine Rx (NASDAQ:BLRX) just reported results for the fourth quarter of 2023.B...
- Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on...
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
When you want to light your afterburners, these ideas will do the trick.
BioLineRx (BLRX) has filed a prospectus for a mixed shelf offering to raise up to $250M, indicating potential growth in their financial capital.
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
BiolineRx, a biopharmaceutical company, reports Q3 2023 financial results, with a GAAP EPS of -$0.01.
- Received FDA Approval of APHEXDA® (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent...
Purchase these top tech stocks now to achieve maximum profits and allow your portfolio to skyrocket given the volatile market.
Penny stocks can make you a millionaire with patience and luck especially when you follow secular trends overall.
BioLineRx announced a license agreement with GloriaBio for the development of motixafortide in Asia, including potential milestones and equity investment.
- License agreement includes $15 million upfront, up to $50 million in potential development and regulatory milestones; up to ~$200 million in potential...
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
BioLineRx (BLRX) added ~23% pre-market Monday after the FDA greenlighted its lead asset Aphexda (motixafortide) for multiple myeloma patients. Read more here.
- On Track for September 9, 2023 PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple...
One of the safest sectors on the market is biotech. Here are three cheap biotech stocks to buy that are good options for investors.
Find a similar success story in some of the market's top penny stocks, and you stand to make a small fortune.
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial stage biopharmaceutical company pursuing life-changing therapies for certain...